XPO1 and Miyoshi myopathy: With the selinexor‐dexamethasone doublet having demonstrated important clinical activity in the later‐relapse setting, and in the context of mechanistic rationales and preclinical evidence supporting combination of XPO1 inhibition with other MM therapies, selinexor has been investigated in multiple triplet combinations for the treatment of early‐ and later‐relapse RRMM, most notably in combination with Vd—compared with Vd alone—in the phase 3 BOSTON trial [61] (Table 2).